We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+7.42%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.34B
AUM Growth
+$140M
Cap. Flow
+$87.9M
Cap. Flow %
3.75%
Top 10 Hldgs %
23.56%
Holding
168
New
20
Increased
60
Reduced
15
Closed
19

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$65.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$38.6M
3
HCA icon
HCA Healthcare
HCA
+$36.9M
4
COR icon
Cencora
COR
+$28.3M
5
DVA icon
DaVita
DVA
+$24M

Top Sells

Rank Stock Value
1
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$67.4M
2
CI icon
Cigna
CI
+$65.2M
3
MRK icon
Merck
MRK
+$47.9M
4
JNJ icon
Johnson & Johnson
JNJ
+$27.9M
5
WTW icon
Willis Towers Watson
WTW
+$18.5M

Sector Composition

Rank Sector Weight
1 Healthcare 87.66%
2 Financials 1.72%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
26
DELISTED
Celgene Corp
CELG
$27.7M 1.18%
310,100
+7,100
+2% +$682K
DVA icon
27
DaVita
DVA
$11.6B
$26.9M 1.15%
407,500
+327,400
+409% +$24M
EW icon
28
Edwards Lifesciences
EW
$52.7B
$26.5M 1.13%
570,003
– –
WCG
29
DELISTED
Wellcare Health Plans, Inc.
WCG
$25.9M 1.11%
134,000
– –
COR icon
30
Cencora
COR
$61.6B
$25.4M 1.08%
+295,000
New +$28.3M
TMO icon
31
Thermo Fisher Scientific
TMO
$220B
$23.6M 1.01%
114,500
+4,500
+4% +$945K
GILD icon
32
Gilead Sciences
GILD
$165B
$23.6M 1.01%
313,400
– –
TFX icon
33
Teleflex
TFX
$5.98B
$23.6M 1.01%
92,500
+750
+0.8% +$197K
AVXS
34
DELISTED
AveXis, Inc. Common Stock
AVXS
$23.5M 1%
190,000
+15,000
+9% +$1.78M
MDCO
35
DELISTED
Medicines Co
MDCO
$22.7M 0.97%
690,000
– –
EPZM
36
DELISTED
Epizyme, Inc
EPZM
$22.6M 0.97%
1,275,000
-50,000
-4% -$844K
ASMB icon
37
Assembly Biosciences
ASMB
$522M
$21.8M 0.93%
36,917
-583
-2% -$361K
MRSN
38
DELISTED
Mersana Therapeutics
MRSN
$20.5M 0.87%
52,000
-1,072
-2% -$423K
WMGI
39
DELISTED
Wright Medical Group Inc
WMGI
$19.8M 0.85%
1,000,000
+300,000
+43% +$6.43M
ALDR
40
DELISTED
Alder Biopharmaceuticals
ALDR
$19.4M 0.83%
1,529,800
+474,800
+45% +$6.87M
BAX icon
41
Baxter International
BAX
$14.2B
$19.3M 0.82%
297,000
+67,000
+29% +$4.53M
SRPT icon
42
Sarepta Therapeutics
SRPT
$1.74B
$19.1M 0.82%
258,000
– –
EHC icon
43
Encompass Health
EHC
$12.4B
$18.7M 0.8%
411,039
+77,934
+23% +$3.34M
JAZZ icon
44
Jazz Pharmaceuticals
JAZZ
$16.9B
$18.7M 0.8%
123,700
– –
INSM icon
45
Insmed
INSM
$28.9B
$18.6M 0.79%
825,000
+211,500
+34% +$5.57M
ASND icon
46
Ascendis Pharma A/S
ASND
$16.6B
$18.5M 0.79%
283,500
+3,500
+1% +$197K
LKFT
47
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.76B
$18.5M 0.79%
185,000
– –
AXGN icon
48
Axogen
AXGN
$2.52B
$18.4M 0.79%
505,000
+27,500
+6% +$843K
ALNY icon
49
Alnylam Pharmaceuticals
ALNY
$29.2B
$17M 0.73%
143,000
+13,000
+10% +$1.68M
BOLD
50
DELISTED
Audentes Therapeutics, Inc
BOLD
$17M 0.72%
565,000
+40,000
+8% +$1.35M
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, Rock Springs Capital Management held 168 positions worth $2.34B, up 6.4% from $2.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management deployed $87.9M of net new capital in Q1 2018, opening 20 new positions and adding to 60 existing holdings. Its largest new stake was AbbVie: 600,000 shares worth $56.8M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 85% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was PRA Health Sciences, Inc., an estimated $7.33M trimmed.

  • Rock Springs Capital Management's largest Q1 2018 buy was AbbVie: 600,000 shares worth $56.8M.
  • Rock Springs Capital Management added most to Bristol-Myers Squibb in Q1 2018, an estimated $38.6M increase.
  • Rock Springs Capital Management's biggest Q1 2018 reduction was PRA Health Sciences, Inc., cutting an estimated $7.33M.
  • Rock Springs Capital Management fully exited Advanced Accelerator Applications S.A. in Q1 2018, selling an estimated $67.4M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $2.34B portfolio in Q1 2018.
  • Rock Springs Capital Management opened 20 new positions and closed 19 in Q1 2018.
  • Rock Springs Capital Management's portfolio value rose 6.4% quarter-over-quarter to $2.34B.

Based on Rock Springs Capital Management's 13F filing for Q1 2018, filed 15 May 2018.